Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: A randomised, double-blind, parallel, controlled study

British Journal of Nutrition

Volumn 102, Issue 11, 2009, Pages 1654-1662

  Guyonnet, Denis ^a   Schlumberger, Armelle ^a   Mhamdi, Leila ^a   Jakob, Stefan ^a   Chassany, Olivier ^b  

^a DANONE RESEARCH   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Adults; Gastrointestinal tract; Probiotics; Randomised controlled trials

Indexed keywords

ACTIVIA; BIFIDOBACTERIUM ANIMALIS DN 173 010 EXTRACT; PROBIOTIC AGENT; UNCLASSIFIED DRUG; YOGHURT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ARTICLE; BLOATING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FERMENTATION; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MILK; PARALLEL DESIGN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; WELLBEING; WOMEN'S HEALTH;

ABDOMINAL PAIN; ADOLESCENT; ADULT; BIFIDOBACTERIUM; DEFECATION; DIGESTION; DOUBLE-BLIND METHOD; FEMALE; FERMENTATION; FLATULENCE; GASTROINTESTINAL TRACT; GASTROINTESTINAL TRANSIT; HUMANS; MIDDLE AGED; PROBIOTICS; QUALITY OF LIFE; YOGURT; YOUNG ADULT;

BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS;

EID: 73749083065     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114509990882     Document Type: Article

References (39)

1. Quigley EM & Flourie B (2007) Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 19, 166-172.
2. Spiller P (2008) Review Article: probiotics and prebiotics in irritable bowel syndrome (IBS). Aliment Pharmacol Ther 28, 385-396.
3. Camilleri M (2006) Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy. J Clin Gastroenterol 40, 264-269.
4. Johansson ML, Nobaek S, Berggren A, et al. (1998) Survival of Lactobacillus plantarum DSM 9843 (299v), and effect on the short-chain fatty acid content of faeces after ingestion of a rose-hip drink with fermented oats. Int J Food Microbiol 42, 29-38.
5. Larsen CN, Nielsen S, Kaestel P, et al. (2006) Dose-response study of probiotic bacteria Bifidobacterium animalis subsp. lactis BB-12 and Lactobacillus paracasei subsp. paracasei CRL-341 in healthy young adults. Eur J Clin Nutr 60, 1284-1293.
6. Olivares M, Diaz-Ropero MA, Gomez N, et al. (2006) Oral administration of two probiotic strains, Lactobacillus gasseri CECT5714 and Lactobacillus coryniformis CECT5711, enhances the intestinal function of healthy adults. Int J Food Microbiol 107, 104-111.
7. Yamano T, Iino H, Takada M, et al. (2006) Improvement of the human intestinal flora by ingestion of the probiotic strain Lactobacillus johnsonii La1. Br J Nutr 95, 303-312.
8. Matsumoto K, Takada T, Shimizu K, et al. (2006) The effects of a probiotic milk product containing Lactobacillus casei strain Shirota on the defecation frequency and the intestinal microflora of sub-optimal health state volunteers: a randomized placebo-controlled cross-over study. Biosci Microflora 25, 39-48.
9. Duez H, Pelletier C, Cools S, et al. (2000) A colony immunoblotting method for quantitative detection of a Bifidobacterium animalis probiotic strain in human faeces. J Appl Microbiol 88, 1019-1027.
10. Pochart P, Marteau P, Bouhnik Y, et al. (1992) Survival of bifidobacteria ingested via fermented milk during their passage through the human small intestine: an in vivo study using intestinal perfusion. Am J Clin Nutr 55, 78-80.
11. Berrada N, Lemeland JF, Laroche G, et al. (1991) Bifidobacterium from fermented milks: survival during gastric transit. J Dairy Sci 74, 409-413.
12. Rochet V, Rigottier-Gois L, Ledaire A, et al. (2008) Survival of Bifidobacterium animalis DN-173 010 in the faecal microbiota after administration in lyophilised form or in fermented product-a randomised study in healthy adults. J Mol Microbiol Biotechnol 14, 128-136.
13. Agrawal A, Houghton LA, Morris J, et al. (2009) Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 29, 104-114.
14. Guyonnet D, Chassany O, Ducrotté P, et al. (2007) Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 26, 475-486.
15. Marteau P, Cuillerier E, Méance S, et al. (2002) Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment Pharmacol Ther 16, 587-593.
16. Méance S, Cayuela C, Raimondi A, et al. (2003) Recent advances in the use of functional foods: effects of the commercial fermented milk with Bifidobacterium animalis strain DN-173 010 and yoghurt strains on gut transit time in the elderly. Microb Ecol Health Dis 15, 15-22.
17. Méance S, Cayuela C, Turchet P, et al. (2001) A fermented milk with a Bifidobacterium probiotic strain DN-173 010 shortened oro-faecal gut transit time in elderly. Microb Ecol Health Dis 13, 217-222.
18. Guyatt GH, Deyo RA, Charlson M, et al. (1989) Responsiveness and validity in health status measurement: a clarification. J Clin Epidemiol 42, 403-408.
19. Irvine EJ, Whitehead WE, Chey WD, et al. (2006) Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 130, 1538-1551.
20. Heaton KW, O'Donnell LJ, Braddon FE, et al. (1992) Symptoms of irritable bowel syndrome in a British urban community: consulters and nonconsulters. Gastroenterology 102, 1962-1967.
21. Guyonnet D, Chassany O, Picard C, et al. (2008) Perceived subject outcomes and impact on health-related quality of life associated with diet using the new Food Benefits Assessment (FBAq) questionnaire: development and psychometric validation. Public Health Nutr 11, 1163-1172.
22. Dupuy HJ (1984) The psychological general well-being (PGWB) index. In Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies, chapter 9, pp. 170-184 [NK Wenger, ME Mattson, CF Furberg and J Elinson, editors]. New York: Le Jacq Publishing.
23. Walters SJ & Brazier JE (2005) Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 14, 1523-1532.
24. Juniper EF, Guyatt GH, Willan A, et al. (1994) Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 47, 81-87.
25. European Medicines Agency (1998) ICH Topic E 9. Statistical Principles for Clinical Trials. Step 5. Note for guidance on statistical principles for clinical trials (CPMP/ICH/363/96). London: EMEA.
26. Goetze O, Fruehauf H, Pohl D, et al. (2008) Effect of a prebiotic mixture on intestinal comfort and general wellbeing in health. Br J Nut 100, 1077-1085.
27. Hernando-Harder AC, von Bunau R, Nadarajah M, et al. (2008) Influence of E. coli strain Nissle 1917 (EcN) on intestinal gas dynamics and abdominal sensation. Dig Dis Sci 53, 443-450.
28. McFarland LV & Dublin S (2008) Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 14, 2650-2661.
29. Cummings JH, Antoine JM, Azpiroz F, et al. (2004) PASSCLAIM-gut health and immunity. Eur J Nutr 43, Suppl. 2, II118-II173.
30. van Kerkhoven LA, Eikendal T, Laheij RJ, et al. (2008) Gastrointestinal symptoms are still common in a general Western population. Neth J Med 66, 18-22.
31. Moayyedi P, Ford AC, Talley NJ, et al. (2008) The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut (epublication ahead of print version 17 December 2008).
32. Nuovo J, Melnikow J & Chang D (2002) Reporting number needed to treat and absolute risk reduction in randomized controlled trials. JAMA 287, 2813-2814.
33. Altman DG, Schulz KF, Moher D, et al. (2001) The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 134, 663-694. (Pubitemid 32322245)
34. Bouglé D, Roland N, Lebeurrier F, et al. (1999) Effect of propionibacteria supplementation on fecal bifidobacteria and segmental colonic transit time in healthy human subjects. Scand J Gastroenterol 34, 144-148.
35. Kim HJ, Camilleri M, McKinzie S, et al. (2003) A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea- predominant irritable bowel syndrome. Aliment Pharmacol Ther 17, 895-904.
36. Sairanen U, Piirainen L, Grasten S, et al. (2007) The effect of probiotic fermented milk and inulin on the functions and microecology of the intestine. J Dairy Res 74, 367-373.
37. Bartram HP, Scheppach W, Gerlach S, et al. (1994) Does yogurt enriched with Bifidobacterium longum affect colonic microbiology and fecal metabolites in healthy subjects? Am J Clin Nutr 59, 428-432.
38. Collado MC, Moreno Y, Cobo JM, et al. (2006) Molecular detection of Bifidobacterium animalis DN-173010 in human feces during fermented milk administration. Food Res Int 39, 530-535.
39. Parkes GC, Brostoff J, Whelan K, et al. (2008) Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol 103, 1557-1567.